Zhongxin Jingwei, January 31 - Near the opening of the afternoon of the 31st, Pien Tze Huang released an announcement on the first quarter of 2024.
Pien Tze Huang said that during the beginning of 2024, the sales momentum of Pien Tze Huang's products will be good, and the market will show a strong sales trend, successfully achieving a "good start". According to the company's preliminary accounting, it is expected that in the first quarter of 2024, the company will achieve a year-on-year increase in net profit attributable to shareholders of listed companies of no less than 25%.
Pien Tze Huang reminded that the company's operating performance data for the first quarter of 2024 is based on market development in line with expectations, the stable development of the traditional Chinese medicine industry, and the stable international situation, and the actual situation in the future is uncertain. The above main operating data is preliminary accounting data, which is only used as a phased financial data for investors' reference, and cannot be used to extrapolate the company's annual performance. Investors should not place undue reliance on this information on business performance** when making investment decisions. Investors are advised to invest rationally and pay attention to risks.
On the evening of the previous day (January 30), Pien Tze Huang released the announcement of the 2023 annual performance express report, and the company achieved a total operating income of 1003.4 billion yuan, an increase of 15 percent year-on-year42%；Net profit attributable to shareholders of listed companies278.4 billion yuan, an increase of 12 percent year-on-year59%。
In May 2023, Pien Tze Huang's core products will increase their prices. Pien Tze Huang said that in view of the main raw materials and labor costs of Pien Tze Huang's products, the company decided that from May 5, 2023, the retail sales of the company's leading product Pien Tze Huang lozenges in the domestic market will be raised from 590 yuan to 760 yuan, and the corresponding increase will be about 170 yuan; Overseas markets*** will be raised by about $35 accordingly.
Regarding the performance changes in the first three quarters of 2023, Pien Tze Huang said that the year-on-year increase in the company's total operating income was mainly due to the strengthening of market planning and the expansion of sales channels, and the increase in sales revenue of the company, its holding subsidiary Fujian Pien Tze Huang Health Technology Co., Ltd., and its holding subsidiary Pien Tze Huang (Zhangzhou) Pharmaceutical.
The year-on-year changes in the company's operating profit, total profit, net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses and basic earnings per share were mainly due to the increase in operating profit due to the increase in sales of the company's core products Pien Tze Huang series products and Pien Tze Huang brand Angong Niuhuang Pill.
In contrast to the performance, on the 31st, Pien Tze Huang's stock price fell intraday.
Screenshot of wind.
Shortly after the opening of the market on January 31, Pien Tze Huang's volume fell to a limit, and the share fell to 19755 yuan, a new low since August 19, 2020. After the announcement of the above-mentioned quarterly results, Pien Tze Huang opened the fall limit, and as of press time, Pien Tze Huang **866% at 20050 yuan shares, with a total market value of 121 billion yuan. (Zhongxin Jingwei app).
The views in this article are for reference only and do not constitute investment advice. )
For more exciting content, please pay attention to the official WeChat of JWVIEW***